en · de · es · fr · pt
aod-9604-notes.peptides6155.com › Topic › Identity And Research Origin — 2026 Update

Identity And Research Origin — 2026 Update

By Editorial Desk · published 2025-08-21 · last reviewed 2025-10-10 · Topic

Everything below concerns synthetic peptide. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.

Updated 2025-10-10. Numbers and descriptions here follow the published literature rather than marketing material.

Identity and Research Origin

Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.

AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.

Regulatory and Analytical Context

In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.

Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.

Aod-9604 at a glance

PropertyValueNotes
Molecular classPeptide fragmentCorresponds to hGH residues 176-191
Common synonymsAOD9604, hGH 176-191Also written as AOD-9604
Typical formLyophilized powderOften supplied in sealed vials
SolubilityWater-solubleDissolves in aqueous buffers
Regulatory statusNot approved as drugBanned in sport; varies by country

Research and Regulatory Context

Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.

AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.

Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.

Related pages on this site

Identity and Research Context

Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.

Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.

AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.

Identity And Research Background

AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.

AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.

Identity and Molecular Context

The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.

Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.

AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.

Supporting material

H2A (aq) + H2O (l) ⇌ H3O+ (aq) + HA− (aq) Ka1 HA− (aq) + H2O (l) ⇌ H3O+ (aq) + A2− (aq) Ka2 The first dissociation constant is typically greater than the second (i.e., Ka1 > Ka2). For example, sulfuric acid (H2SO4) can donate one proton to form the bisulfate anion (HSO−4), for which Ka1 is very large; then it can donate a second proton to form the sulfate anion (SO2−4), wherein the Ka2 is intermediate strength. The large Ka1 for the first dissociation makes sulfuric a strong acid. In a similar manner, the weak unstable carbonic acid (H2CO3) can lose one proton to form bicarbonate anion (HCO−3) and lose a second to form carbonate anion (CO2−3). Both Ka values are small, but Ka1 > Ka2 . A triprotic acid (H3A) can undergo one, two, or three dissociations and has three dissociation constants, where Ka1 > Ka2 > Ka3.

==== Israel ==== In the 2006 war against Hezbollah, Israel alleges that cyber-warfare was part of the conflict, where the Israel Defense Forces (IDF) intelligence estimates several countries in the Middle East used Russian hackers and scientists to operate on their behalf. As a result, Israel attached growing importance to cyber-tactics, and became, along with the U.S., France and a couple of other nations, involved in cyber-war planning. Many international high-tech companies are now locating research and development operations in Israel, where local hires are often veterans of the IDF's elite computer units. Richard A. Clarke adds that "our Israeli friends have learned a thing or two from the programs we have been working on for more than two decades." In September 2007, Israel carried out an airstrike on a suspected nuclear reactor in Syria dubbed Operation Orchard. U.S. industry and military sources speculated that the Israelis may have used cyberwarfare to allow their planes to pass undetected by radar into Syria. Following US President Donald Trump's decision to pull out of the Iran nuclear deal in May 2018, cyber warfare units in the United States and Israel monitoring internet traffic out of Iran noted a surge in retaliatory cyber attacks from Iran. Security firms warned that Iranian hackers were sending emails containing malware to diplomats who work in the foreign affairs offices of US allies and employees at telecommunications companies, trying to infiltrate their computer systems.

Hemoglobin C/ beta thalassemia: common in Mediterranean and African populations generally results in a moderate form of anemia with splenomegaly. Hemoglobin D/ beta thalassemia: common in the northwestern parts of India and Pakistan (Punjab region). Hemoglobin E/ beta thalassemia: common in Cambodia, Thailand, and parts of India, it is clinically similar to β thalassemia major or β thalassemia intermedia. Hemoglobin S/ beta thalassemia: common in African and Mediterranean populations, it is clinically similar to sickle-cell anemia. Delta-beta thalassemia is a rare form of thalassemia in which there is a reduced production of both the delta and beta globins. It is generally asymptomatic. There are two clinically significant combinations involving the sickle cell gene:

== Further reading == Peters, U H (1992), "[Introduction of shock therapy and psychiatric emigration]", Fortschritte der Neurologie-Psychiatrie, vol. 60, no. 9 (published Sep 1992), pp. 356–365, doi:10.1055/s-2007-999155, PMID 1398417, S2CID 71208271 "Manfred J. Sakel", Journal of Clinical and Experimental Psychopathology, vol. 15, no. 3, p. 319, 1954, PMID 13221647 Fink, M (1984), "Meduna and the Origins of Convulsive Therapy", American Journal of Psychiatry, 141(9): 1034-1041 (This historical and biographical paper discusses the introduction of the shock treatment in psychiatry, the role of a theory of the biological antagonism between epilepsy and schizophrenia, and the contributions of Ladislas J. Meduna, Sakel, Ugo Cerletti, and Lucio Bini.) Doroshow, DB: Performing a Cure for Schizophrenia: Insulin Coma Therapy on the Wards. Journal of the History of Medicine and Allied Sciences, Advance Access published online on November 14, 2006 Jones, K. Insulin coma therapy in schizophrenia. J. Royal Soc. Med, 93: 147-149, 2000.

== History == The approach of reducing resistance during sets was described in the late 1940s by Henry Atkins, editor of Body Culture magazine, who called it the multi-poundage system. In the 1980s, drop sets formed part of Joe Weider's Weider System.

Sources: en.wikipedia.org

Supporting material

== Pathophysiology == SJS is a type IV hypersensitivity reaction in which a drug or its metabolite stimulates cytotoxic T cells (i.e. CD8+ T cells) and T helper cells (i.e. CD4+ T cells) to initiate autoimmune reactions that attack self tissues. In particular, it is a type IV, subtype IVc, delayed hypersensitivity reaction dependent in part on the tissue-injuring actions of natural killer cells. This contrasts with the other types of SCARs disorders, i.e., the DRESS syndrome which is a Type IV, Subtype IVb, hypersensitivity drug reaction dependent in part on the tissue-injuring actions of eosinophils and acute generalized exanthematous pustulosis which is a Type IV, subtype IVd, hypersensitivity reaction dependent in part on the tissue-injuring actions of neutrophils. Like other SCARs-inducing drugs, SJS-inducing drugs or their metabolites stimulate CD8+ T cells or CD4+ T cells to initiate autoimmune responses. Studies indicate that the mechanism by which a drug or its metabolites accomplishes this involves subverting the antigen presentation pathways of the innate immune system. The drug or metabolite covalently binds with a host protein to form a non-self, drug-related epitope. An antigen presenting cell (APC) takes up these alter proteins; digests them into small peptides; places the peptides in a groove on the human leukocyte antigen (i.e. HLA) component of their major histocompatibility complex (i.e. MHC); and presents the MHC-associated peptides to T-cell receptors on CD8+ T cells or CD4+ T cells.

=== Environmental contaminants === Since American kestrels are carnivores, toxic chemical runoff ingested by their prey can concentrate at high levels in their blood. Wild kestrels are subject to immunomodulation, or an altered immune response, to polybrominated diphenyl ethers (PBDEs), a group of industrial flame retardants that may leach from factories into the environment. When PBDEs accumulate in body tissues of kestrels, the T-cell mediated immune response decreases in efficiency. As a result, kestrels that ingest PBDEs may not respond sufficiently to viruses or other invading microorganisms. In addition, certain PBDEs may suppress the growth and development of the spleen and bursa in American kestrels. While PBDEs can affect immune response and suppress growth of certain organs, they can also affect the thyroid system of American Kestrels. Exposure to PBDEs in vivo can alter the thyroid system and retinol concentrations in kestrels. This leads to oxidative stress, lipid peroxidation, and changes in glutathione metabolism. These systems are important in early development, growth, regulation of metabolism, thermoregulation, and reproduction. Oxidative stress is also known to contribute to cancers and neurological diseases. Exposure to polychlorinated biphenyls (PCBs) might also affect American Kestrel reproduction. It was found that PCBs affect the function of carotenoids in kestrels. This led to changes in coloration, especially during breeding season for adults. PCB-exposed males where duller and contributed less to egg incubation than unexposed males.

A milkette (also referred to as dairy milker, creamette or creamers) is a single serving of milk (2%) or cream (10% and 18%) in 12 millilitres (0.42 imp fl oz; 0.41 US fl oz) or 15 millilitres (0.53 imp fl oz; 0.51 US fl oz) containers used for coffee and tea. The single cup of milk is stored in a sealed (foil cover) plastic cup of milk or cream with long shelf life but must be refrigerated.

=== Metalorganic addition === Interaction of ethylene oxide with organomagnesium compounds, which are Grignard reagents, can be regarded as nucleophilic substitution influenced by carbanion organometallic compounds. The final product of the reaction is a primary alcohol:

Deborah Levy (born 6 August 1959); novelist, playwright and poet of South African and Lithuanian Jewish ancestry; her plays were staged by the Royal Shakespeare Company; novels included Beautiful Mutants, Swallowing Geography and Billy & Girl; recent fiction has included the Booker-shortlisted novels Swimming Home and Hot Milk, as well as the Booker-longlisted The Man Who Saw Everything and short-story collection Black Vodka;The Guardian ranked The Cost of Living number 84 in list of "The 100 best books of the 21st century". Gertrude Rachel Levy (5 November 1883 – 10 October 1966), author and cultural historian writing about comparative mythology, matriarchy, epic poetry and archaeology; worked with Department of Antiquities in Mandatory Palestine. Paul Levy, food writer, biographer; long rabbinical pedigree Bernard Lewis (31 May 1916 – 19 May 2018); specialised in Oriental studies; public intellectual and political commentator; wrote over ten books on history of Islam and the interaction between Islam and the West; was called "the West's leading interpreter of the Middle East". Others have accused Lewis of having revived the image of cultural inferiority of Islam and of emphasising the dangers of jihad. His advice was frequently sought by neoconservative policymakers, including the Bush administration. However, his active support of the Iraq War and neoconservative ideals have since come under scrutiny. Maureen Lipman, (born 10 May 1946) is an English actress, columnist and comedian, who has published several collections of her comedy sketches, and autobiography.

Sources: en.wikipedia.org

Supporting material

It is highly encouraged that a physician interested in learning Mohs surgery should spend extended time observing, cutting, processing, and staining Mohs specimens. It is vital that the histotechnologist prepare high-quality slides. The histology block must be correctly mounted, cut, and stained the first time, as there is no second chance in Mohs histology. It is not a procedure that can be properly mastered in a short period of time.

a Rho GTPase, usually Rac1 or Rac2 (Rac stands for Rho-related C3 botulinum toxin substrate) Five phagocytic oxidase subunits: gp91phox (NOX2) p22phox (CYBA) p40phox (NCF4) p47phox (NCF1) p67phox (NCF2)

Integral membrane proteins are permanently attached to the membrane. Such proteins can be separated from the biological membranes only using detergents, nonpolar solvents, or sometimes denaturing agents. They can be classified according to their relationship with the bilayer:

can replace separate correlations for individual properties. Conversely, a variety of experimental measurements (e.g., density, heat capacity, vapor pressure) can be incorporated into the same fit; in principle, this would allow one to predict hard-to-measure properties like heat capacity in terms of other, more readily available measurements (e.g., vapor pressure).

Sources: en.wikipedia.org

Frequently asked questions

What is AOD-9604?

AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.

Is AOD-9604 the same as growth hormone?

No, it is a small fragment of the full growth hormone protein. It does not appear to stimulate growth or increase growth hormone levels in the same way. Its actions are thought to be more limited to metabolic pathways.

How is AOD-9604 regulated?

Regulatory status varies. It is not approved for medical use in the United States or many other countries. It is banned in sport by WADA, and its sale as a supplement or research chemical may be subject to legal restrictions.

Is AOD-9604 approved for medical use?

No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.

Network